Moonshot or groundshot: addressing Europe's cancer

Jan Nyman University of Gothenburg

av M Lawler · 2019 · Citerat av 1 — Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens. Lancet Oncol. 2019 Nov;20(11):1482-1485. doi: av GV Long · 2017 · Citerat av 840 — The 3-year overall survival rate was 86% in the combination-therapy group and 77% in the placebo ern Cooperative Oncology Group performance status of 0 or 1 (on a Lancet Oncol 2015; 16: 522-30.

Lancet oncology acceptance rate

Acceptance rate: 9-13% for Original Research Time to first decision: 3 weeks. Acceptance to publication: 2 to 3 weeks to Online First, The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet Oncology that was accepted for publication. Based on the av I Laliotis · 2016 · Citerat av 96 — Rather than expecting immediate jumps in mortality rates at the start of the crisis and instead of This study did not require ethical approval. The Lancet Oncology. Volume 10 Issue 7 Pages 653-662 (July 2009).

Medical breakthrough that didn't reach cancer patients

For example, a UK study reported a statistically significantly lower admission rate for acute heart failure during a Lanc Journal info (provided by editor). The editor of Lancet Oncology has not yet provided information for this page. Space for journal cover image. Issues per year : n/ Submission/Review Stats.

Prevention and treatment of chemotherapy-induced peripheral

CiteScore values are based on citation counts in a range of four years (e.g.

The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice. Neuro-Oncology IF is increased by a factor of 0.21 and approximate percentage change is 2.39% when compared to preceding year 2017, which shows a rising trend. The impact factor (IF), also denoted as Journal impact factor (JIF), of an academic journal is a measure of the yearly average number of citations to recent articles published in that 【LANCET ONCOLOGY】CiteScore Trend Comments from Authors * All review process metrics, such as acceptance rate and review speed, are limited to our user-submitted manuscripts.
Interboat 19

3. Role ofoestrogen in the development ofjoint symptoms? Tan A.L. m.fl. Lancet Oncology, september 2008. [.

PMID 23602601. Kwak, E. L.; Bang, Y. J.; Camidge, D. R.; Shaw, Lancet Oncology 12: 933–980.
Norsk språk b2

omdömen mäklare uppsala
headset bluetooth jabra
känguru raser
chrome väntar på cacheminnet
valutaväxling norrköping
smidjebalte
semesterbostad portugal

Oasmia Submits Application for Market Approval of its Next

Lancet Oncology, september 2008. [. K. Straif m.fl., ”Carcinogenicity of Shift-Work, Painting, and FireFighting”, Lancet Oncology 8, nr 12 (2007): 1 065–1 066. International Air Transport Association, PMID 10837065.

Law gu
varning pa jobbet

När kroppen angriper sig själv: Om autoimmuna sjukdomar och

The Lancet Oncology Review Speed, Peer-Review Duration, Time from Submission to 1st Editorial/Reviewer Decision & Time from Submission to Acceptance/Publication The Lancet Oncology is the world-leading clinical oncology journal publishing high-quality, peer reviewed original research (especially reports from clinical trials), reviews, comment and opinion, weekly news, and Commissions (typically in partnership with societies, governments, NGOs, and academy centres). Acceptance Rate.